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Abstract
Background: Interactions between CXCR4 and its ligand CXCL12 have been shown to be involved in cancer
progression in colorectal cancer (CRC). We performed a comparative CXCL12/CXCR4 expression analysis and
assessed the effect of external CXCL12 stimulation on migration of CRC cells without and with CXCR4 inhibition.
Methods: Expression of CXCL12/CXCR4 was assessed by quantitative real-time PCR, ELISA and
immunohistochemistry in resection specimens of 50 CRC patients as well as in the corresponding normal tissues
and in three human CRC cell lines with different metastatic potential (Caco-2, SW480 and HT-29). Migration assays
were performed after stimulation with CXCL12 and CXCR4 was inhibited by siRNA and neutralizing antibodies.
Results: In CRC tissues CXCL12 was significantly down-regulated and CXCR4 was significantly up-regulated
compared to the corresponding normal tissues. In cell lines CXCR4 was predominantly expressed in SW480 and
less pronounced in HT-29 cells. CXCL12 was only detectable in Caco-2 cells. CXCL12 stimulation had no impact on
Caco-2 cells but significantly increased migration of CXCR4 bearing SW480 and HT-29 cells. This effect was
significantly abrogated by neutralizing anti-CXCR4 antibody as well as by CXCR4 siRNAs (P < 0.05).
Conclusions: CXCR4 expression was up-regulated in CRC and CXCL12 stimulation increased migration in CXCR4
bearing cell lines. Migration was inhibited by both neutralizing CXCR4 antibodies and CXCR4 siRNAs. Thus, the
expression and functionality of CXCR4 might be associated with the metastatic potential of CRC cells and CXCL12/
CXCR4 interactions might therefore constitute a promising target for specific treatment interventions.
Background
Colorectal cancer (CRC) represents one of the most fre-
quent malignancies worldwide with distant recurrence
primarily affecting the liver as the predominant cause of
CRC related mortality. The 5-year survival rate of 90%
in patients with tumor restricted to the colon decreases
to 10% in the presence of distant metastasis [1].
Recently, various cancer-related studies demonstrated
that specific chemokines and their receptors may be
involved in the molecular mechanisms that control
metastasis in the early stages of cancer development [2].
In this respect, the homeostatic chemokine CXCL12, a
non-ELR+ CXC chemokine, has been implicated in pro-
moting angiogenesis and metastasis [3,4]. CXCL12, also
known as stromal derived factor 1 (SDF-1), is the only
chemokine that is essential for survival [5] and a highly
efficacious chemoattractant for T cells and thymocytes
[6,7]. It is expressed by stromal cells such as fibroblasts
and endothelial cells and signals exclusively via its
G-protein-linked transmembrane receptor CXCR4 [8].
Expression of functional CXCR4 has been reported in
various types of cancer cells [9-12], but also in immune
cells such as peripheral blood lymphocytes, unprimed
T cells, dendritic cells and lymphocytic leukemia B cells,
where CXCR4 mediates spontaneous migration beneath
bone marrow and stromal cells [13]. In infectious dis-
ease CXCR4 is employed by the human immunode-
fiency virus (HIV) to gain entry to cells [14] and in stem
cell localization CXCR4 plays an important role for B-
cell lymphopoiesis and bone marrow myelopoiesis [5].
In breast cancer, CXCR4 signaling was shown to play a
crucial role in distant recurrence by mediating actin
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polymerisation and pseudopodia formation, thus, leading
to chemotactic and invasive responses [3].
Recently, CXCR4 expression was associated with
advanced tumor stage and the development and recur-
rence of lymphatic or distant colorectal liver metastases
(CRLM) [15-17]. Thus, it was reported that CXCR4 is
differentially expressed in CRC and significantly corre-
lates with survival, recurrence and liver metastasis
[15,18]. Moreover, it was shown that concomitant and
high expression of CXCR4 and VEGF is a strong and
independent predictor of early distant relapse in CRC
[19] and recent evidence indicates that CXCR4 may also
play a role in tumor angiogenesis of CRC [20].
Despite increasing knowledge about the expression of
CXCL12/CXCR4 in CRC and its involvement of CXCR4
in the invasion and dissemination of CRC the precise
mechanisms of CXCL12/CXCR4 interactions and subse-
quent metastasis are not entirely known. We therefore
performed a comparative CXCL12/CXCR4 expression
analysis and investigated how external addition of
CXCL12 would promote CXCR4-mediated migration of
CRC cell lines with different metastatic capabilities and
how inhibition of CXCR4 by either CXCR4 siRNAs or
neutralizing anti-CXCR4 antibodies would influence
their migration potential.
Methods
Materials and patients
Surgical specimens and corresponding normal tissue
from the same samples were collected from patients
who underwent surgical resection at our department
between 2003 and 2006. No patient underwent any spe-
cific cancer therapy prior to the resection. Our patient
collectives comprised patients with CRC of different
cancer stages (n = 50). In cases of organ confined CRC
patients underwent resection of the primary tumor.
Adjacent, disease free tissue samples of the colon and
rectum served as control groups, respectively. Further,
10 specimens from patients with liver ruptures, focal
nodular hyperplasia and haemangiomas as well as 10
unaffected tumor neighbor tissues from primary esopha-
geal, pancreatic, gastric and colorectal carcinoma,
respectively, were assessed. Informed consent for tissue
procurement was obtained from all patients. The study
was approved by the ethics commission of the Ärzte-
kammer of the Saarland. The clinical variables presented
in Table 1 were obtained from the clinical and patholo-
gical records and are in accordance with the UICC/
TNM classification [21]. Cell culture assays were per-
formed on non-metastatic cell line Caco-2 and meta-
static cell lines SW480 and HT-29. Their metastatic
potential has been investigated in murine liver metasta-
sis models [22-24].
Tissue preparation
Tissue samples were collected immediately after resec-
tion, snap frozen in liquid nitrogen and then stored at
-80°C until they were processed under nucleic acid ster-
ile conditions for RNA and protein extraction. Tumor
samples were taken from vital areas of histopathologi-
cally confirmed adenocarcinomas. As corresponding
normal tissue we used adjacent unaffected mucosa,
2-3 cm distal to the resection margin from the same
resected adenocarcinoma. All tissues obtained were
reviewed by an experienced pathologist (M.W.) and
examined for the presence of tumor cells. As minimum
criteria for usefulness for our studies we only chose
tumor tissues in which tumor cells occupied a major
component (>75%) of the tumor sample.
Single-strand cDNA synthesis
Total RNA was isolated using RNeasy columns from
Qiagen (Hilden, Germany) according to the manufac-
turer’s instructions. RNA integrity was confirmed spec-
trophotometrically and by electrophoresis on 1% agarose
Table 1 Clinical characteristics of patients with colorectal
carcinomas
Factor CRC2 n = 50
Localization of primary tumor
Colon 23
Rectum 27
Gender
Male 30
Female 20
Age, years3 63.9 (47-78)
Hepatitis (A,B or C)
Positive 6
Negative 44
Largest tumor diameter (cm)3 4.7 (1.2-9.1)
TNM1 stage of primary tumor
I 8
II 16
III 16
IV 10
Grading
I 0
II 22
III 27
Lymphatic permeation
Positive 28
Negative 22
Vascular invasion
Positive 7
Negative 43
1Tumor-node-metastasis; 2Colorectal carcinoma;
3Median with range in parentheses.
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gels. For cDNA synthesis 5 μg of each patient total RNA
sample were reverse-transcribed in a final reaction
volume of 50 μL containing 1× TaqMan RT buffer,
2.5 μM/L random hexamers, 500 μM/L each dNTP,
5.5 mM/L MgCl2, 0.4 U/μl RNase inhibitor, and 1.25 U/μL
Multiscribe RT. All RT-PCR reagents were purchased
from Applied Biosystems (Foster City, CA). The reaction
conditions were 10 min at 25°C, 30 min at 48°C, and 5 min
at 95°C.
Real-time PCR
All Q-RT PCR assays containing the primer and probe
mix were purchased from Applied Biosystems, (Applied
Biosystems, Foster City, CA) and utilized according to
the manufacturer’s instructions. PCR reactions were car-
ried out using 10 μL 2× Taqman PCR Universal Master
Mix No AmpErase® UNG and 1 μL gene assay (Applied
Biosystems, Foster City, CA), 8 μL Rnase-free water and
1 μL cDNA template (50 mg/L). The theoretical basis of
the qRT assays is described in detail elsewhere [25]. All
reactions were run in triplicate along with no template
controls and an additional reaction in which reverse
transcriptase was omitted to assure absence of genomic
DNA contamination in each RNA sample. For the signal
detection, ABI Prism 7900 sequence detector was pro-
grammed to an initial step of 10 min at 95°C, followed
by 40 thermal cycles of 15 s at 95°C and 10 min at 60°C
and the log-linear phase of amplification was monitored
to obtain CT values for each RNA sample.
Gene expression of all target genes was analyzed in
relation to the levels of the slope matched housekeeping
genes phosphomannomutase (PMM1) and b2-Microglo-
bulin (b2 M) [26]. Data analysis was performed accord-
ing to the relative standard curve method. Data are
presented in relation to the respective housekeeping
genes.
Isolation of total protein
Protein lysates from frozen tissues were extracted with
the radioimmunoprecipitation (RIPA) cell lysis and
extraction buffer from Pierce (Pierce, Rockford, USA).
Total protein content was assessed by using the Pierce
BCA protein assay reagent kit (Pierce, Rockford, USA).
Sandwich-Type Enzyme-Linked Immunosorbent Assay
The chemokine protein levels in the different tissue
lysates were determined by sandwich-type enzyme-linked
immunosorbent assays (ELISA) according to the manu-
facturer’s instructions. Samples were assayed in duplicate
with all values calculated as the mean of the two mea-
surements. CXCL12 levels were assayed using a validated
commercial ELISA (Duo Set R&D Systems, DY350, Min-
neapolis, Minn., USA). The absorbance was read
at 450 nm in a 96-well microtiter plate reader. The
chemokine concentration from each tissue lysate was
normalized to the total protein content of each sample.
Immunohistochemistry/Immunocytochemistry
Operative specimens were routinely fixed in formalin
and subsequently embedded in paraffin. Before staining,
4-μm thick paraffin-embedded tissue sections were
mounted on Superfrost Plus slides, deparaffinized and
rehydrated in graded ethanol to deionized water. The
sections were microwaved with an antigen retrieval solu-
tion (Target Retrieval, Dakocytomation, Carpinteria, CA,
USA) and after blocking of endogenous peroxidase
activity with 3% hydrogen peroxide, the sections were
sequential treated with avidin and biotin (Avidin/Biotin
blocking kit, Vector Laboratories Inc., Burlingame, CA,
USA). In addition the specimens were further blocked
for 30 min at room temperature with normal rabbit
serum. Overnight incubation at 4°C with primary goat
polyclonal anti-human CXCR4 antibody (1:300, AB1671,
Abcam, Cambridge, UK) was followed by incubation of
secondary biotinylated rabbit anti-goat IgG antibody and
the avidin-biotin-peroxidase reaction (Vectastain ABC
ELITE Kit, Vector Laboratories, Burlingame, CA, USA).
After colour reaction with aminoethylcarbazol solution
(Merck, Darmstadt, Germany), tissues were counter-
stained with haematoxylin. Immunocytochemical stain-
ing of CRC cells was performed using culture slides
from Becton Dickinson (Becton Dickinson, Heidelberg,
Germany). After blocking of endogenous peroxidase
activity and blocking for 30 min at room temperature
with normal rabbit serum, cells were overnight incu-
bated at 4°C with primary goat polyclonal anti-human
CXCR4 antibody (1:300, AB1671, Abcam, Cambridge,
UK). Following incubation of secondary biotinylated
rabbit anti-goat IgG antibody and the avidin-biotin-
peroxidase reaction (Vectastain ABC ELITE Kit, Vector
Laboratories, Burlingame, CA, USA) and all further
steps were carried out as described above for the immo-
histochemical staining procedure.
Negative controls were conducted in all cases omitting
primary antibody. For evaluation of immunocytochem-
ical staining the total number of cells per 5 high-power
fields (using ×40 -HPF objective magnification) was
determined. Cells were considered positive, when they
demonstrated strong and exclusive labelling.
Cell migration assays
Cell migration assays were performed in triplicate using
BD Falcon cell culture inserts containing polyethylene
terephthalate membranes (8 μm pore size) from BD
Biosciences (Bedford, MA, USA). Caco-2, HT-29 and
SW480 cells at a concentration of 50000 cells per ml in
500 μl medium with antibiotics but without FCS were
placed in the top of a two-chamber assay system and
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incubated for 48 hours with and without CXCL12 (350-
NS-10, R&D Systems, Wiesbaden, Germany) in 800 μl
medium without FCS placed in the lower chamber.
CXCL12 concentrations in the receiver wells were
10 ng, 50 ng and 100 ng per ml, respectively. After the
incubation period, the non-migrated cells on the upper
surface of the filters were removed using a cotton swab.
Migrated cells, which are adherent to the lower surface
of the filters, were stained with a 0.1% crystal violet
solution (Merck, Darmstadt, Germany). The number of
these migrated cells was quantified microscopically by
counting them in 10 high-power microscopic fields.
Medium with 20% FCS placed in the lower chamber of
the two-chamber assay system served as a positive con-
trol and reference in the migration assays.
Cell proliferation assays
Cell proliferation assays (Roche Diagnostics GmbH,
Mannheim, Germany) were performed in triplicate
using flat-bottomed 96-well microtiter plates for cultur-
ing Caco-2, HT-29 and SW480 cells in the presence of
CXCL12 at 37°C for 48 hours. Subsequently, bromo-
deoxyuridine (BrdU) was added to the cells and the cells
were reincubated for 24 hours. During this labeling per-
iod the pyrimidine analogue BrdU is incorporated in
place of thymidine into the DNA of proliferating cells.
After removing the culture media, cells were fixed and
anti-BrdU-POD was added to bind to the BrdU incorpo-
rated in newly synthesized cellular DNA. Immune com-
plexes were detected by the subsequent substrate
reaction and the reaction product was quantified by
photometrically measuring the absorbance of the devel-
oped color.
Cell inhibition assays
Inhibition assays were performed in analogy to the cell
migration assays using BD Falcon cell culture inserts
from BD Biosciences. Similar to the migration assays
Caco-2, HT-29 and SW480 cells in 500 μl medium
without FCS were mixed with anti-CXCR4 antibodies
(MAB171, R&D systems) applied in a final concentra-
tion of 6 μg per ml and placed in the upper chamber of
a two-chamber assay system. After incubation for
48 hours with and without CXCL12 in 800 μl medium
without FCS placed in the lower chamber steps were
continued as mentioned above for the migration assays
and migrated CRC cells were quantified microscopically
by counting the cells that had migrated into the filters.
siRNA assays
CXCR4 siRNA transfection of Caco-2, HT-29 and
SW480 cells was performed according to the HiPerFect
Transfection Reagent Handbook from Qiagen (Qiagen,
Hilden, Germany) and the Dharmacon DharmaFECT
siRNA transfection protocol (Thermo Fisher Scientific,
Waltham, USA). Briefly, cells were trypsinized, counted
and then diluted in antibiotic-free complete medium
containing serum to achieve the appropriate plating den-
sity in 100 μl of solution. On average, 6 × 104 cells per
well of a 24-well plate or 5 × 105 cells per well of a 6-well
plate, respectively, were seeded and overnight incuba-
ted under their normal growth conditions. On the
day of transfection, four different CXCR4 siRNAs
(Qiagen, SI00052220 (1), SI00052227 (2), SI02664235 (7),
SI02664242 (8)) were diluted to a final concentration of
10 nM in 100 μl culture medium without serum, respec-
tively. 3 μl of HiPerFect (Qiagen) for the transfection of
SW480 cells and 5 μl of Dharmacon DharmaFECT
siRNA transfection reagent (Thermo Fisher Scientific)
for the transfection of Caco-2 and HT-29 cells were
added to the diluted siRNA reactions, respectively. Sam-
ples were incubated for 5-10 minutes at room tempera-
ture to allow formation of transfection complexes.
Hence, the complexes were added drop-wise to the cells
and incubated for three hours under their normal growth
conditions. Gene silencing was monitored after 48 and
72 hours after transfection at the mRNA and at the pro-
tein level using Realtime PCR and western blotting,
respectively. Further, gene silencing was monitored
visually by observing the effect on a cell death control.
Further, control samples with untransfected cells, a
mock-transfection with only transfection reagent, a nega-
tive control siRNA and control samples with MAPK1
siRNA were used. A detailed overview of siRNA control
experiments is presented in Table 2. Subsequent migra-
tion assays were performed as described above.
Western Blot Analysis
Gene silencing was monitored 72 hours after transfec-
tion at the protein level using western blotting. Total
protein (25 μg/lane) was separated by SDS-PAGE using
a 10% gel and blotted onto nitrocellulose membranes
(Hybond ECL, Amersham Biosciences, Piscataway, NJ,
USA). Membranes were blocked by incubation in Tris-
buffered saline (TBS) containing 5% non fat dry milk
and 0.1% Tween 20 for 2 h at room temperature and
then incubated overnight at 4°C with primary goat poly-
clonal anti-human CXCR4 antibody (1:300, AB1671,
Abcam, Cambridge, UK). Blots were then washed and
incubated at room temperature for 1 h with donkey
anti-goat HRP antibody (diluted 1:5000, sc-2056, Santa
Cruz Biotechnology, Santa Cruz, CA USA). Bands were
visualized by ECL Western blotting analysis systems
(Amersham Biosciences, Piscataway, NJ, USA). The
human cell lysate HL-60 (sc-2209, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) served as positive control.
Quantification of band intensities has been performed
on three independent samples using image J software.
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Calculations and Statistical Methods
Chemokine receptor expression profiles in the different
groups are shown as mean and standard error of the
mean (SEM). Statistical calculations were done with the
MedCalc software package. Where appropriate, either
the Student’s t-test or the Wilcoxon’s rank sum test was
applied to test for group differences of continuous vari-
ables. A P value of 0.05 or less was considered significant.
Results
CXCL12/CXCR4 expression in CRC tissues
Q-RT-PCR analysis of CRC tissue specimens revealed
significant up-regulation of CXCR4 and significant
down-regulation of CXCL12 compared to corresponding
normal tissues (Figure 1A). These results were verified
for CXCL12 on the protein level as shown by ELISA
assays which demonstrated significant CXCL12 down-
regulation in CRC tissues compared to the correspond-
ing normal tissues (Figure 1B). Detection of CXCR4
expression was assessed by immunohistochemical stain-
ing. Immunostaining of the CRC tissues revealed
positive cytoplasmic staining in 28 out of 50 CRC speci-
mens (56%) as shown for a representative example in
Figure 1C. However, no significant difference in CXCR4
expression was detected according to the metastatic
behaviour. Patients with synchronous or metachronous
colorectal liver metastases expressed CXCR4 in their
primary tumor with no significant difference with
respect to CRC patients who did not develop metastases.
Organ-specific expression of CXCL12
CXCL12 mRNA and protein expression as determined by
RT-PCR and ELISA was investigated in different human
organs such as pancreas, stomach, colon/rectum and eso-
phagus related to the liver. On the protein level CXCL12
was found to exhibit peak levels of expression in the liver
compared to stomach, esophagus, pancreas, colon and rec-
tum (Figure 2). However, on the mRNA level CXCL12 did
not show a markedly higher expression in the liver in
comparison to other gastrointestinal organs or glands cor-
responding to previous results [27].
CXCL12/CXCR4 expression in CRC cell lines
In non-metastatic cell line Caco-2 low CXCL12 expres-
sion was detected on the mRNA level by PCR and on the
protein level in the cell culture supernatant by ELISA
(Figure 3A and 3B, respectively). In metastatic cell lines
SW480 and HT-29 CXCL12 mRNA and protein expres-
sion was below detection limit (Figure 3A and 3B, respec-
tively). In contrast, CXCR4 mRNA expression was
detected in HT-29 and SW480 cells with the latter dis-
playing significant overexpression relative to B2M (Figure
3A). When CXCR4 protein expression was assessed by
immunocytochemical staining, CXCR4 positive staining
was observed in 22% of Caco-2 cells, 74% of HT-29 cells
and 80% of SW480 cells as quantified microscopically
and shown for a representative example in Figure 3C.
Likewise, CXCR4 protein expression as determined by
western blot analysis revealed similar expression rates in
HT-29 and SW480 cells. Variation in CXCR4 mRNA and
protein data may be due to posttranscriptional and post-
translational modifications as well as to the relative
amplification modus of the qRT-PCR results with respect
to housekeeping gene B2M.
CXCR4 protein inhibition abrogates migration of
colorectal cancer cells
All three cell lines were stimulated with 10, 50 and
100 ng/ml CXCL12, respectively, and incubated for
48 hours. While Caco-2 cells were not stimulated by
any concentration of CXCL12 (Figure 4A), we observed
a significant CXCL12 dose-independent stimulation of
migration for HT-29 and SW480 cells (Figure 4B and
4C, respectively) (P < 0.05). Thus, CXCL12 was shown
to be chemotactic for HT-29 and SW480 cells.
When we added neutralizing anti-CXCR4 antibody
prior to performance of cell migration assays, the
CXCL12 stimulated migration of HT-29 and SW480
Table 2 Applied RNAi control experiments - overview
Control
experiment
Type Example
Positive control
siRNA
siRNA that is known to provide high knockdown of its target gene Hs_MAPK1 siRNA (Qiagen)
OrderNo. 1022564
Negative control
siRNA
a nonsilencing siRNA with no homology to any known mammalian gene AllStars Negative control siRNA
(Qiagen)
OrderNo. 1027280
Transfection
control siRNA
siRNA that is used to measure the transfection efficiency, e.g. by siRNA AllStars Hs Cell Death Control
siRNA (Qiagen)
OrderNo. 1027298
Mock transfection
control
control experiment where cells go through the transfection process without addition of
siRNA
Untransfected cells
control
control experiment where gene expression analysis is carried out on cells that have not
gone through the transfection process
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Figure 1 CXC12/CXCR4 expression in colorectal cancer (CRC) tissue specimens as determined by (A) Q-RT-PCR for CXCL12 and CXCR4,
(B) ELISA analysis for CXCL12 and (C) immunohistochemistry for CXCR4. (A) Q-RT-PCR data are expressed as mean +/- standard error of
the mean (SEM), *P < 0.05, n = 50. Fold increase above 1 indicates gene overexpression in affected tissues related to unaffected neighbor
tissues. (B) Detection of CXCL12 protein concentrations (pg/ml pro mg total protein) in total cell lysates of CRC and adjacent normal tissues from
CRC patients (n = 50). Protein data are expressed as mean +/- SEM, *P < 0.05. (C) Detection of CXCR4 protein expression in representative CRC
specimens as assessed by immunohistochemical staining with CXCR4-specific antibodies showing positive cytoplasmic staining in CRC and in
unaffected corresponding tissues (original magnification × 200 and × 400).
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cells was significantly abrogated at all CXCL12 concen-
trations under investigation (Figure 4B and 4C, respec-
tively) (P < 0.05). Application of anti-CXCR4 antibodies
had no impact on the migration potential of Caco-2
cells (Figure 4A).
CXC receptor-4 gene silencing abrogates migration of
colorectal cancer cells
To analyze if the chemotactic effect of CXCL12 on the
migration of HT-29 and SW480 cells could be counter-
acted by the down-regulation of the mRNA of corre-
sponding receptor CXCR4, we applied four different
CXCR4 siRNAs. The mean percent CXCR4 knockdown
related to the siRNA negative control was 78% for
Caco-2 cells, 80% HT-29 cells and 84% for SW480 cells
as determined by RT-PCR 48 hours after transfection
on the mRNA level (Figure 5A). On the protein level
gene silencing was monitored 72 hours after transfection
in western blot analyses (Figure 5B). Application of
CXCR4 siRNAs had no impact on the migration poten-
tial of Caco-2 cells (Figure 6A). In contrast, the
CXCL12 stimulated migration of HT-29 and SW480
cells was significantly abrogated by all four different
CXCR4 siRNAs at all CXCL12 concentrations under
investigation (Figure 6B and 6C, respectively) (P < 0.05).
Proliferative rate of colorectal cancer cells after CXCR4
blockage by mRNA silencing and inhibition antibodies
CXCR4 blockage by mRNA silencing or anti-CXCR4 anti-
bodies might restrain the proliferation of CRC cell lines,
so that the decreased migration capacity of cancer cells
might result from a lower proliferative rate. To ensure that
the significantly abrogated migration capacity of HT-29
Figure 2 CXCL12 protein expression in different human organs
related to the liver as determined by ELISA. CXCL12 protein
concentrations (pg/ml per mg total protein) were measured in total
cell lysates of normal liver, pancreas, stomach, colon/rectum and
esophagus tissues of 10 patients, respectively (n = 10). Protein data
are expressed as mean +/- SEM, *P < 0.05.
Figure 3 CXC12/CXCR4 expression in Caco-2, HT-29 and SW480
cells as determined by (A) Q-RT-PCR for CXCL12 and CXCR4,
(B) ELISA analysis for CXCL12 and (C) immunocytochemistry for
CXCR4. (A) Q-RT-PCR data are expressed as mean +/- standard error
of the mean (SEM), *P < 0.05. Fold increase above 1 indicates gene
overexpression related to housekeeping gene B2M. (B) Detection of
CXCL12 protein concentrations in pg/ml in cell culture supernatant
of Caco-2, HT-29 and SW480 cells. Protein data are expressed as
mean +/- SEM. (C) Detection of CXCR4 protein expression in
representative cell culture slides of Caco-2, HT-29 and SW480 cells
as assessed by immunocytochemical staining with CXCR4-specific
antibodies.
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and SW480 cells after CXCR4 mRNA silencing by all four
different CXCR4 siRNAs is not resulting from a lower
proliferative rate with respect to the untransfected cells,
we investigated their proliferative capacity before and after
siRNA transfection. In addition, we also included cell line
Caco-2 in this survey. Likewise, we investigated the prolif-
erative capacity of Caco-2, HT-29 and SW480 cells before
and after CXCR4 blockage by neutralizing anti-CXCR4
antibody. Here, cells without anti-CXCR4 antibody served
as reference. As presented in figure 7 there is no marked
difference between the proliferation rates of Caco-2 (Fig-
ure 7A), HT-29 (Figure 7B) and SW480 (Figure 7C) cells
before or after CXCR4 mRNA silencing or CXCR4 block-
age by anti-CXCR4 antibody. Thus, the significantly abro-
gated migration capacity of HT-29 and SW480 cells after
CXCR4 mRNA silencing or CXCR4 blockage by anti-
CXCR4 antibody is not resulting from a reduced prolifera-
tion rate.
Discussion
The importance of the CXCL12/CXCR4 axis in tumor
progression and metastasis has been emphasized. Recent
evidence also suggests that the CXCL12/CXCR4 system
is involved in the progression and metastasis of CRC
[15,20,28].
Thus, the aim of this study was to conduct a com-
parative CXCL12/CXCR4 expression analysis and to
investigate the functional role of CXCR4 in metastatic
and non-metastatic CRC derived cell lines. For this pur-
pose the migration potential of these cell lines was
tested under conditions where CXCR4 was inhibited on
the mRNA as well as on the protein level. On the
mRNA level, CXCR4 silencing was achieved by CXCR4
RNA interference while on the protein level inhibition
of CXCR4 protein activity was achieved using an anti-
CXCR4 antibody.
As shown initially, CXCL12 protein is significantly
higher expressed in the liver in relation to other intest-
inal organs or glands, thus supporting potential CXCL12
involvement in the homing of CRC cells to the liver.
Subsequently, we observed significant up-regulation of
CXCR4 and significant down-regulation of CXCL12 in
CRC tissues. This inverse expression pattern is sup-
ported by previous studies, where CXCR4 was shown to
be highly up-regulated in all T-stages of CRC tissues
[16] and CXCL12 expression levels were shown to be
low at the base of the crypts and increased in the more
differentiated apical intestinal epithelial cells [29,30]. In
compliance with the low CXCL12 expression status in
tissues we observed low or no CXCL12 expression,
respectively, in three human CRC derived cell lines,
non-metastatic cell line Caco-2 and metastatic cell lines
SW480 and HT-29. While low CXCL12 expression was
detected in Caco-2 cells on the mRNA and on the pro-
tein level, CXCL12 was below the detection limit in
HT-29 and SW480. It was hypothesized that changes in
epithelial CXCL12 expression might contribute to CRC
disease progression by allowing CRC cells to more read-
ily sense CXCL12 from exogeneous sources hereby pro-
moting metastasis [31]. Wendt et al. have shown that
the reduced CXCL12 expression pattern in CRC tissues
and cells is due to DNA hypermethylation in primary
CRC and carcinoma-derived cell lines. Thus, it was
demonstrated that inhibition or ablation of DNA
methyltransferases prevent promoter methylation and
restore CXCL12 expression. In addition, re-expression
of functional, endogeneous CXCL12 in CRC cells was
shown to reduce metastatic tumor formation signifi-
cantly while silencing CXCL12 greatly enhanced the
metastatic potential of CRC cells [31]. Moreover, endo-
geneous CXCL12 was shown to provide a barrier to
metastasis by increasing anoikis via activation of a Bim-
mediated intrinsic apoptotic pathway [32,33]. These
results may constitute a plausible explanation for our
observation of significantly reduced CXCL12 expression
rates in CRC tissues and carcinoma-derived cell lines.
Concordantly, an elevated migratory signaling response
to ectopic CXCL12 was also shown to contribute to the
metastatic potential of CXCR4-expressing mammary
carcinoma cells, subsequent to epigenetic silencing of
autocrine CXCL12 [34].
For CXCR4 we observed an inverse expression pattern
in the three CRC-derived cell lines. Thus, expression in
non-metastatic cell line Caco-2 was significantly lower
compared to the metastatic cell lines under investiga-
tion. Also drug-resistant invasive HT-29 cells with a
metastatic behaviour in immunodeficient mice were
shown to exhibit high CXCR4 expression [35]. Responsi-
ble for promoting invasion in drug-resistant colon carci-
noma cells is the autocrine CXCR4 ligand macrophage
migration-inhibitory factor (MIF) as shown by Dessein
et al. Impairing the MIF-CXCR4 signaling pathway, e.g.
by silencing CXCR4, abolished this aggressive pheno-
type. To date, in various cancer entities aberrantly
expressed chemokine receptors were demonstrated to
contribute directly to the development of organ selective
distant metastasis by interaction with their organ selec-
tively expressed chemokine ligands. As a consequence of
the low CXCR4 expression, Caco-2 cells showed no
increase in migration in response to CXCL12 stimula-
tion. In contrast, CXCL12 significantly increased cell
migration in the CXCR4 expressing metastatic cell lines
SW480 and HT-29. While a stimulative effect of
CXCL12 on migration of CRC cell lines was described
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Figure 4 CXCR4 protein inhibition abrogates migration of colorectal cancer cells. (A) Percent Caco-2 cell migration related to a positive
control containing 20% FCS (PC) without inhibition and after inhibition with anti-CXCR4 antibody. (B) Percent HT-29 cell migration related to PC
without inhibition and after inhibition with anti-CXCR4 antibody. (C) Percent SW480 cell migration related to PC without inhibition and after
inhibition with anti-CXCR4 antibody.
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before [36], these effects were not significant and refer
only to one CXCL12 concentration (100 ng/ml). More-
over, these tests were performed on CRC cell lines
LS174T, SW620 and SW480 but not on cell lines
HT-29 and Caco-2. To further investigate the functional
role of CXCR4 we performed inhibition assays with
anti-CXCR4 antibodies added previously to CXCL12 sti-
mulation. The addition of the inhibition antibodies sig-
nificantly blocked the CXCL12-dependent stimulation of
HT-29 and SW480 cell migration but had no impact on
Caco-2 migration. Our results correlate with inhibition
studies performed on SW480 cells [37], where chemo-
taxis induced by CXCL12 was also shown to be blocked,
although not as complete as we have shown for both
SW480 and HT-29 cells. Likewise, Kim et al [38]
reported on a partial inhibitory effect of anti-CXCR4
antibodies on CXCL12 stimulated melanoma and CRC
cell migration (38%). However, to date no study ana-
lyzed the effect of CXCR4 gene silencing on CXCL12
mediated cell migration of CRC cells. Thus, we investi-
gated if the chemotactic effect of CXCL12 on the migra-
tion of HT-29 and SW480 cells could be counteracted
by the down-regulation of the CXCR4 mRNA. Applying
four different CXCR4 siRNAs we achieved a mean
percent CXCR4 knockdown of 78-84% and a significant
abrogation of CXCL12 stimulated migration of HT-29
and SW480 for all four different CXCR4 siRNAs at all
CXCL12 concentrations under investigation. On the
other hand, application of CXCR4 siRNAs had no
impact on the migration potential of Caco-2 cells. Thus,
we have demonstrated the functional status of the
CXCR4 receptor on CRC cell lines in response to
CXCL12 on the mRNA level.
In CRC patients, no significant difference in CXCR4
expression was detected according to the metastatic
behaviour. Based on our in vitro results CRC patients
with metastasis may be expected to express more
CXCR4 in their tumor cells compared to CRC patients
without metastasis. However, many other important fac-
tors contribute to the metastatic properties of tumor tis-
sues and influence their metastatic potential. When a
CRC cell is turned metastatic, CXCR4 may be an impor-
tant factor for the homing of such a tumor cell to its
favourite organ destination, the liver.
Our results are well in line with recent findings
demonstrating a role of CXCL12 in promoting cell
migration and tumor growth of CRC metastasis in vivo
in a murine model [39]. However, while we observed no
CXCR4-dependent proliferation of CRC cells, Shen et al.
demonstrated CXCR4-induced proliferation for pancrea-
tic cancer cells, where it was linked to AKT and ERK
dependent pathways [40]. Moreover, CXCR4 knockdown
by small interfering RNA was shown to inhibit cell pro-
liferation and invasion of oral squamous cell carcinoma
cells [41]. A recent study demonstrated that CXCL12/
CXCR4 interactions may also promote early extravasa-
tion of liver metastatic epithelial tumor cells which
determines a critical step in formation of organ-specific
metastases [42]. Currently, various small-molecule che-
mokine receptor antagonist compounds are undergoing
development in phase I to III studies in infectious and
autoimmune diseases and a CCR5 inhibitor is already in
the clinic for the treatment of HIV-infected patients.
Conclusions
In conclusion, our results provide evidence that CXCR4
is up-regulated in CRC and stimulation of CXCR4 bear-
ing cancer cells with CXCL12 led to increased migra-
tion, an effect which could be inhibited both by CXCR4
siRNA and neutralizing CXCR4 antibodies. Interestingly,
CXCR4 was predominantly expressed in cell lines with
metastatic potential and consequently, these cell lines
showed increased migration after external CXCL12 sti-
mulation. Our results suggest that the metastatic poten-
tial of CRC cells may be associated with the aberrant
expression of CXCR4 and subsequently the ability of
cells to interact with CXCL12 via autocrine and/or para-
crine mechanisms.
Figure 5 Demonstration of CXCR4 knockdown as determined
by mRNA and protein analysis. (A) Mean percent CXCR4
knockdown related to siRNA negative control (NC) as determined
by mRNA analysis in Caco-2, HT-29 and SW480 cells. (B) CXCR4
protein expression after CXCR4 siRNA silencing as determined by
Western Blot analysis in Caco-2, HT-29 and SW480 cells related to
untransfected total cell lysates. Total cell lysates of untransfected
cells and one representative example of CXCR4 siRNA transfected
cells of each cell line were immunoblotted with antibodies
specifically recognizing chemokine receptor CXCR4. Acute leucemia
cell line HL60 served as positive control for the detection of CXCR4.
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Figure 6 CXCR4 mRNA silencing abrogates migration of colorectal cancer cells. (A) Percent Caco-2 cell migration related to positive
control containing 20% FCS (PC) without transfection and after transfection with 4 different CXCR4 siRNAs. (B) Percent HT-29 cell migration
related to PC without transfection and after transfection with 4 different CXCR4 siRNAs. (C) Percent SW480 cell migration related to PC without
transfection and after transfection with 4 different CXCR4 siRNAs.
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Figure 7 Proliferative rate of colorectal cancer cells after CXCR4 mRNA silencing or CXCR4 blockage by inhibition antibodies.
Knockdown of endogeneous CXCR4 expression by four different CXCR4 siRNAs or CXCR4 blockage by ant-CXCR4 inhibition antibodies does not
decelerate the proliferation rate of (A) Caco-2 cells, (B) HT-29 cells and (C) SW480 cells in relation to untransfected cells without inhibition
antibody (control).
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